MTX-463

Asset

Inhibits WISP-1 to block fibrosis progression

Stage: Phase 2
Modality: Antibody
Target: CCN4; 1
Indication: 0
Trials: 1
Developer

Indications

1

Idiopathic pulmonary fibrosis
Phase 2, prnewswire.com, 7 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets1
Competitors3

Every asset’s record: target, stage, trials and the evidence behind it.